Critical Contrast: AzurRx BioPharma (AZRX) versus Its Rivals
AzurRx BioPharma (NASDAQ: AZRX) is one of 104 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare AzurRx BioPharma to similar businesses based on the strength of its valuation, dividends, institutional ownership, earnings, risk, profitability and analyst recommendations.
This table compares AzurRx BioPharma and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AzurRx BioPharma Competitors||-2,432.86%||-68.24%||-8.07%|
This table compares AzurRx BioPharma and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|AzurRx BioPharma||N/A||-$14.59 million||-2.69|
|AzurRx BioPharma Competitors||$8.31 billion||$1.11 billion||158.94|
AzurRx BioPharma’s peers have higher revenue and earnings than AzurRx BioPharma. AzurRx BioPharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
8.2% of AzurRx BioPharma shares are held by institutional investors. Comparatively, 44.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 9.1% of AzurRx BioPharma shares are held by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of recent ratings and target prices for AzurRx BioPharma and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AzurRx BioPharma Competitors||902||3891||6881||183||2.54|
AzurRx BioPharma presently has a consensus price target of $8.00, suggesting a potential upside of 106.72%. As a group, “Pharmaceuticals” companies have a potential upside of 19.41%. Given AzurRx BioPharma’s stronger consensus rating and higher probable upside, research analysts clearly believe AzurRx BioPharma is more favorable than its peers.
AzurRx BioPharma peers beat AzurRx BioPharma on 8 of the 12 factors compared.
AzurRx BioPharma Company Profile
AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.